1[1]Stanton A, Jensen C, Nussberger J. Blood pressure lowering in essential hypertension with an oral renin inhibitor,aliskiren. Hypertension. 2003, 42(6):1137-1143.
2[2]Jafar TH, Schmid CH, Levey AS. Effect of angiotensinconverting enzyme inhibitors on progression of nondiabetic renal disease. Ann Intern Med. 2002, 137(4):298-299.
3[3]Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet, 2002, 359(9311):1004-1010.
4[4]Jay N, Cohn MD, Gianni T. A randomized trial of the angiotensin-receptor blocker valsartan chronic heart failure.N Engl J Med, 2001, 345(23): 1667-1675A.
5[5]Scott DS, Duolao W, Peter F, et al. Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients.Circulation, 2004,110:2180-2183.
6[6]Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004, 363(9426):2022-2031.
7[7]David A, Scott DS, Lars K, et al. Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction. The Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Circulation, 2004,110:1572-1578.
8[8]Brenner BM, Cooper ME, Keane WF, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med,2001, 345(12):861-891.
9[9]Ouzan J, Perault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002, 15 (4 Pt 1):333-339.
10[10]Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999, 341 (10):709-717.
6Ferrario CM.Role of angiotensin Ⅱ in cardiovascular disease therapeutic inplications of more than a century of research.J Renin Angiotensin Aldosterone Syst,2006,7:3-14.
7Iwata M,Yoshikawa T,Baba A,et al.Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sadden death in patients with idiopathic dilated cardiomyopathy.J Am Coll Cardiol,2001,37:418-424.
8Yang X,Wang F,Chang H,et al.Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation.J Hypertens,2008,26:1629-1635.
9Fu ML.Anti-peptide antibodies against an autoimmune epitope on human muscarinie receptor mimic functional autoantibodies against the same epitope in patients with idiopathic dilated cardiomyopathy.Eur Heart J,1995,16:89-91.
